LTR Pharma (ASX:LTP) rallied on news that a second medical practitioner has been authorised to prescribe SPONTAN® under the Therapeutic Goods Administration (“TGA”) Special Access Scheme (“SAS”)..
- A second men’s health expert and clinical key opinion leader in Australia is now authorised to prescribe SPONTAN® – a novel treatment for erectile dysfunction (“ED”)
- LTR Pharma is supporting strategic engagement with a network of healthcare providers familiar with SPONTAN® and its clinical benefits, via the TGA’s SAS
- SPONTAN® identified as a new innovation for unmet needs in ED due to:
- On demand rapid onset of action
- Decrease in side effect profile
Dr Tom Silva, an expert in men’s health, Senior Lecturer in General Practice at the University of Queensland and Director of Kangaroo Point Medical Centre, said: “SPONTAN® meets the needs of my patients where regular PDE5 inhibitor tablets do not.”
LTR Pharma Chairman, Lee Rodne said: ” We are thrilled to see SPONTAN® being utilised by medical experts like Dr Silva. This represents another significant step in our strategy to introduce SPONTAN® to the market through a carefully managed approach working with knowledgeable medical practitioners.”